{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:22:03Z","timestamp":1791951723714,"version":"4.3.4"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"abstract":"\n Importance<\/jats:title>\n Liver transplant for colorectal cancer with liver metastases was abandoned in the 1990s due to poor overall survival. From 2006, liver transplant for in nonresectable colorectal liver metastases has been reexamined through different prospective trials.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine predictive factors for transplant long-term survival and cure after liver transplant.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a prospective, nonrandomized controlled cohort study derived from different clinical trials on liver transplant for colorectal liver metastases from 2006 to 2020 at Oslo University Hospital. The trials differed in prognostic inclusion criteria, but the design was otherwise identical regarding follow-up scheme to determine disease recurrence, overall survival, and survival after relapse. Final data analysis was performed on December 31, 2021. All patients with colorectal liver metastases from comparable prospective liver transplant studies were included.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Liver transplant.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and measures<\/jats:title>\n Disease-free survival, overall survival, and survival time after recurrence were determined in all participants.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 61 patients (median [range] age, 57.8 [28.7-71.1] years; 35 male [57.4%]) underwent liver transplant at Oslo University Hospital. Posttransplant observation time ranged from 16 to 165 months, and no patient was lost to follow-up. Median disease-free period, overall survival, and survival after relapse were 11.8 (95% CI, 9.3-14.2) months, 60.3 (95% CI, 44.3-76.4) months, and 37.1 (95% CI, 4.6-69.5) months, respectively. Negative predictive factors for overall survival included the following: largest tumor size greater than 5.5 cm (median OS, 25.3 months; 95% CI, 15.8-34.8 months;\n P<\/jats:italic>\n &amp;lt;.001), progressive disease while receiving chemotherapy (median OS, 39.8 months; 95% CI, 28.8-50.7 months;\n P<\/jats:italic>\n = .02), plasma carcinoembryonic antigen values greater than 80 \u03bcg\/L (median OS, 26.6 months; 95% CI, 22.7-30.6 months;\n P<\/jats:italic>\n &amp;lt;.001), liver metabolic tumor volume on positron emission tomography of greater than 70 cm\n 3<\/jats:sup>\n (26.6 months; 95% CI, 11.8-41.5 months;\n P<\/jats:italic>\n &amp;lt;.001), primary tumor in the ascending colon (17.9 months; 95% CI, 0-37.5 months;\n P<\/jats:italic>\n &amp;lt;.001), tumor burden score of 9 or higher (23.3 months; 95% CI, 19.2-27.4 months;\n P<\/jats:italic>\n = .02), and 9 or more liver lesions (42.5 months; 95% CI, 17.2-67.8 months;\n P<\/jats:italic>\n = .02). An Oslo score of 0 or Fong Clinical Risk Score of 1 yielded 10-year survival of 88.9% and 80.0%, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and relevance<\/jats:title>\n Results of this nonrandomized controlled trial suggest that selected patients with liver-only metastases and favorable pretransplant prognostic scoring had long-term survival comparable with conventional indications for liver transplant, thus providing a potential curative treatment option in patients otherwise offered only palliative care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamasurg.2023.2932","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T13:30:44Z","timestamp":1690378244000},"page":"e232932","source":"Crossref","is-referenced-by-count":95,"title":["Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant"],"prefix":"10.1001","volume":"158","author":[{"given":"Svein","family":"Dueland","sequence":"first","affiliation":[{"name":"Transplant Oncology Research Group, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway"},{"name":"Section for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Magnus","family":"Smedman","sequence":"additional","affiliation":[{"name":"Transplant Oncology Research Group, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway"},{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trygve","family":"Syversveen","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Grut","sequence":"additional","affiliation":[{"name":"Department of Radiology, Vestre Viken Hospital Trust, Drammen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Hagness","sequence":"additional","affiliation":[{"name":"Transplant Oncology Research Group, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway"},{"name":"Section for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l-Dag","family":"Line","sequence":"additional","affiliation":[{"name":"Transplant Oncology Research Group, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, Oslo, Norway"},{"name":"Section for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"issue":"6","key":"soi230047r1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"soi230047r2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.surg.2011.12.018","article-title":"The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review.","volume":"151","author":"Quan","year":"2012","journal-title":"Surgery"},{"issue":"12","key":"soi230047r3","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery vs surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomized, controlled, phase 3 trial.","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"soi230047r4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jnci\/djq456","article-title":"Randomized trial of 2 induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.","volume":"103","author":"Masi","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"soi230047r5","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"13","key":"soi230047r6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab vs FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"soi230047r7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"soi230047r8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/SLA.0b013e31828ee17c","article-title":"Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study.","volume":"257","author":"Le Treut","year":"2013","journal-title":"Ann Surg"},{"key":"soi230047r9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/ajt.16978","article-title":"OPTN\/SRTR 2020 annual data report: liver.","volume":"22","author":"Kwong","year":"2022","journal-title":"Am J Transplant"},{"issue":"3","key":"soi230047r10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.surg.2017.05.006","article-title":"Liver transplantation in patients with liver metastases from neuroendocrine tumors: a systematic review.","volume":"162","author":"Moris","year":"2017","journal-title":"Surgery"},{"issue":"1","key":"soi230047r11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000347207","article-title":"Liver transplantation for perihilar cholangiocarcinoma.","volume":"31","author":"Gores","year":"2013","journal-title":"Dig Dis"},{"issue":"4","key":"soi230047r12","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001133","article-title":"Liver transplantation for cholangiocarcinoma: charting a path with lessons learned from center experience.","volume":"7","author":"Ziogas","year":"2021","journal-title":"Transplant Direct"},{"issue":"5","key":"soi230047r13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1 Pt 2","key":"soi230047r14","first-page":"1567","article-title":"Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver?","volume":"23","author":"M\u00fchlbacher","year":"1991","journal-title":"Transplant Proc"},{"issue":"12","key":"soi230047r15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/tri.2008.21.issue-12","article-title":"Liver transplantation for primary and metastatic liver cancers.","volume":"21","author":"Hoti","year":"2008","journal-title":"Transpl Int"},{"issue":"5","key":"soi230047r16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver transplantation for nonresectable liver metastases from colorectal cancer.","volume":"257","author":"Hagness","year":"2013","journal-title":"Ann Surg"},{"issue":"2","key":"soi230047r17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/ajt.15682","article-title":"Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis.","volume":"20","author":"Dueland","year":"2020","journal-title":"Am J Transplant"},{"issue":"2","key":"soi230047r18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00259-017-3843-9","article-title":"The prognostic value of 18F-FDG PET\/CT prior to liver transplantation for nonresectable colorectal liver metastases.","volume":"45","author":"Grut","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"soi230047r19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"issue":"5","key":"soi230047r20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/SLA.0000000000000786","article-title":"Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?","volume":"261","author":"Dueland","year":"2015","journal-title":"Ann Surg"},{"issue":"8","key":"soi230047r21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/lt.24791","article-title":"Liver transplantation for colorectal liver metastasis: survival without recurrence can be achieved.","volume":"23","author":"Toso","year":"2017","journal-title":"Liver Transpl"},{"issue":"11","key":"soi230047r22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S2468-1253(21)00219-3","article-title":"Liver transplantation for nonresectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines.","volume":"6","author":"Bonney","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"soi230047r23","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/bjs.10769","article-title":"Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma.","volume":"105","author":"Dueland","year":"2018","journal-title":"Br J Surg"},{"issue":"3","key":"soi230047r24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/bjs.10651","article-title":"Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases.","volume":"105","author":"Grut","year":"2018","journal-title":"Br J Surg"},{"issue":"11","key":"soi230047r25","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/tri.v34.11","article-title":"Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases.","volume":"34","author":"Dueland","year":"2021","journal-title":"Transpl Int"},{"issue":"20","key":"soi230047r26","doi-asserted-by":"publisher","first-page":"5042","DOI":"10.3390\/cancers14205042","article-title":"PET-uptake in liver metastases as method to predict tumor biological behavior in patients transplanted for colorectal liver metastases developing lung recurrence.","volume":"14","author":"Dueland","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"soi230047r27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1245\/s10434-010-1409-1","article-title":"Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases.","volume":"18","author":"D\u2019Angelica","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"soi230047r28","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1245\/s10434-014-4173-9","article-title":"Pulmonary metastasectomy in colorectal cancer patients with previously resected liver metastasis: pooled analysis.","volume":"22","author":"Salah","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"soi230047r29","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/tri.v34.9","article-title":"Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score.","volume":"34","author":"Lanari","year":"2021","journal-title":"Transpl Int"},{"issue":"6","key":"soi230047r30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamasurg.2021.0267","article-title":"Survival outcomes after portal vein embolization and liver resection compared with liver transplant for patients with extensive colorectal cancer liver metastases.","volume":"156","author":"Dueland","year":"2021","journal-title":"JAMA Surg"},{"issue":"2","key":"soi230047r31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/bjs5.2019.3.issue-2","article-title":"Long-term quality of life after liver transplantation for nonresectable colorectal metastases confined to the liver.","volume":"3","author":"Dueland","year":"2018","journal-title":"BJS Open"},{"issue":"1","key":"soi230047r32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/bjs.10962","article-title":"Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver.","volume":"106","author":"Bj\u00f8rnelv","year":"2019","journal-title":"Br J Surg"},{"issue":"3","key":"soi230047r33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/bjs5.50278","article-title":"Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study).","volume":"4","author":"Smedman","year":"2020","journal-title":"BJS Open"},{"issue":"1","key":"soi230047r34","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1097\/SLA.0000000000001165","article-title":"A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept.","volume":"262","author":"Line","year":"2015","journal-title":"Ann Surg"},{"issue":"2","key":"soi230047r35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/SLA.0000000000002861","article-title":"Paradigm shift in the management of irresectable colorectal liver metastases: Living Donor Auxiliary Partial Orthotopic Liver Transplantation in Combination With 2-stage Hepatectomy (LD-RAPID).","volume":"270","author":"K\u00f6nigsrainer","year":"2019","journal-title":"Ann Surg"},{"issue":"2","key":"soi230047r36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/SLA.0000000000005726","article-title":"Auxilliary liver transplantation according to the RAPID procedure in noncirrhotic patients: technical aspects and early outcomes.","volume":"277","author":"Settmacher","year":"2023","journal-title":"Ann Surg"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2807723\/jamasurgery_dueland_2023_oi_230047_1694030416.05466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:08:12Z","timestamp":1694603292000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2807723"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2023.2932","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}